CN113795287A - 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病 - Google Patents

皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病 Download PDF

Info

Publication number
CN113795287A
CN113795287A CN202080034543.9A CN202080034543A CN113795287A CN 113795287 A CN113795287 A CN 113795287A CN 202080034543 A CN202080034543 A CN 202080034543A CN 113795287 A CN113795287 A CN 113795287A
Authority
CN
China
Prior art keywords
mtor inhibitor
albumin
pharmaceutical composition
rapamycin
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080034543.9A
Other languages
English (en)
Chinese (zh)
Inventor
N·P·德赛
侯世和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Priority to CN202510438859.9A priority Critical patent/CN120267635A/zh
Publication of CN113795287A publication Critical patent/CN113795287A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M5/2448—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/284—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CN202080034543.9A 2019-03-19 2020-03-18 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病 Pending CN113795287A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510438859.9A CN120267635A (zh) 2019-03-19 2020-03-18 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962820842P 2019-03-19 2019-03-19
US201962820838P 2019-03-19 2019-03-19
US62/820,838 2019-03-19
US62/820,842 2019-03-19
PCT/US2020/023366 WO2020191053A1 (en) 2019-03-19 2020-03-18 Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510438859.9A Division CN120267635A (zh) 2019-03-19 2020-03-18 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病

Publications (1)

Publication Number Publication Date
CN113795287A true CN113795287A (zh) 2021-12-14

Family

ID=72519161

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080034543.9A Pending CN113795287A (zh) 2019-03-19 2020-03-18 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病
CN202510438859.9A Pending CN120267635A (zh) 2019-03-19 2020-03-18 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510438859.9A Pending CN120267635A (zh) 2019-03-19 2020-03-18 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病

Country Status (9)

Country Link
US (1) US20220054404A1 (https=)
EP (1) EP3941551A4 (https=)
JP (2) JP2022525549A (https=)
KR (1) KR102936433B1 (https=)
CN (2) CN113795287A (https=)
AU (1) AU2020241730B2 (https=)
CA (1) CA3133988A1 (https=)
MX (1) MX2021011230A (https=)
WO (1) WO2020191053A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3009356T3 (en) 2015-06-29 2025-03-26 Abraxis Bioscience Llc Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
KR102936433B1 (ko) 2019-03-19 2026-03-09 아브락시스 바이오사이언스, 엘엘씨 질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여
BR112022007710A2 (pt) 2019-10-28 2022-07-12 Abraxis Bioscience Llc Composições farmacêuticas de albumina e rapamicina
TW202123935A (zh) * 2019-11-11 2021-07-01 美商亞伯辛生物科學有限責任公司 用於奈米粒子組合物之生物標記
CN120187414A (zh) * 2022-11-25 2025-06-20 克利凯生物公司 用于靶向炎症性巨噬细胞的纳米平台以及包含其的用于预防或治疗炎症性疾病的组合物
KR20250081554A (ko) * 2023-11-29 2025-06-05 주식회사 에스엔바이오사이언스 시롤리무스 및 알부민을 포함하는 나노입자, 이를 포함하는 피하투여용 약제학적 조성물 및 이의 제조방법

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684730A (zh) * 2002-09-04 2005-10-19 梅里迪安医学技术公司 药品输送装置
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
CN104814930A (zh) * 2007-03-07 2015-08-05 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
CN105246468A (zh) * 2013-03-14 2016-01-13 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
US20170119803A1 (en) * 2013-02-19 2017-05-04 Amrita Vishwa Vidyapeetham University Nanoparticle formulations for delivering multiple therapeutic agents
CN107106771A (zh) * 2014-08-18 2017-08-29 温德加普医疗股份有限公司 便携式药物混合和递送装置及相关方法
TW201737940A (zh) * 2016-04-08 2017-11-01 基利科學股份有限公司 治療癌症、炎症疾病及自體免疫疾病之組合物及方法
CN107921006A (zh) * 2015-06-29 2018-04-17 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
CN107921050A (zh) * 2015-06-29 2018-04-17 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
CN108024999A (zh) * 2015-06-29 2018-05-11 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
US20180177771A1 (en) * 2015-06-29 2018-06-28 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
WO2018153984A1 (en) * 2017-02-23 2018-08-30 Universität Bern Mtor inhibitor-corticoid combination therapy for multiple sclerosis
TW201840319A (zh) * 2017-02-24 2018-11-16 德商拜耳廠股份有限公司 Atr激酶抑制劑與鐳-223鹽之組合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
RU2732908C2 (ru) * 2014-10-07 2020-09-24 ЭйАй ТЕРАПЬЮТИКС, ИНК. Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
EP3518923A4 (en) 2016-09-28 2020-06-17 Abraxis BioScience, LLC METHOD FOR TREATING MITOCHONDRIAL AND METABOLIC DISORDERS
TW202015659A (zh) * 2018-05-22 2020-05-01 美商亞伯辛生物科學有限責任公司 用於治療肺高血壓之方法及組合物
KR102936433B1 (ko) 2019-03-19 2026-03-09 아브락시스 바이오사이언스, 엘엘씨 질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684730A (zh) * 2002-09-04 2005-10-19 梅里迪安医学技术公司 药品输送装置
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
CN104814930A (zh) * 2007-03-07 2015-08-05 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
US20170119803A1 (en) * 2013-02-19 2017-05-04 Amrita Vishwa Vidyapeetham University Nanoparticle formulations for delivering multiple therapeutic agents
CN105246468A (zh) * 2013-03-14 2016-01-13 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
CN107106771A (zh) * 2014-08-18 2017-08-29 温德加普医疗股份有限公司 便携式药物混合和递送装置及相关方法
CN108024999A (zh) * 2015-06-29 2018-05-11 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
CN107921006A (zh) * 2015-06-29 2018-04-17 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
CN107921050A (zh) * 2015-06-29 2018-04-17 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
US20180177771A1 (en) * 2015-06-29 2018-06-28 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
TW201737940A (zh) * 2016-04-08 2017-11-01 基利科學股份有限公司 治療癌症、炎症疾病及自體免疫疾病之組合物及方法
WO2018153984A1 (en) * 2017-02-23 2018-08-30 Universität Bern Mtor inhibitor-corticoid combination therapy for multiple sclerosis
TW201840319A (zh) * 2017-02-24 2018-11-16 德商拜耳廠股份有限公司 Atr激酶抑制劑與鐳-223鹽之組合

Also Published As

Publication number Publication date
KR102936433B1 (ko) 2026-03-09
CN120267635A (zh) 2025-07-08
KR20210139367A (ko) 2021-11-22
WO2020191053A1 (en) 2020-09-24
US20220054404A1 (en) 2022-02-24
CA3133988A1 (en) 2020-09-24
AU2020241730A1 (en) 2021-10-28
JP2022525549A (ja) 2022-05-17
EP3941551A1 (en) 2022-01-26
JP2025118604A (ja) 2025-08-13
EP3941551A4 (en) 2023-01-18
MX2021011230A (es) 2022-03-11
AU2020241730B2 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
KR102936433B1 (ko) 질환의 치료를 위한 mTOR 억제제 및 알부민을 포함하는 나노입자의 피하 투여
JP7561628B2 (ja) 肺高血圧症を処置するための方法および組成物
KR102352249B1 (ko) 연령 관련 병태를 치료하기 위한 흡입가능한 라파마이신 제제
JP2020050680A (ja) 膀胱がんを処置する方法
KR102475256B1 (ko) 미토콘드리아 및 대사 장애를 치료하는 방법
EP3417859A1 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
KR20150119177A (ko) 흑색종을 치료하는 방법
KR102837015B1 (ko) mTOR 억제제 및 알부민의 나노입자의 투여를 통한 중추 신경계 장애의 치료 방법
US20230293449A1 (en) Biomarkers for nanoparticle compositions
Deng et al. Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival
EP4516292A1 (en) Instant nanoparticle composition and preparation method therefor
TW202421656A (zh) 用於癌症治療之組合療法
RU2830582C2 (ru) Способы и композиции для лечения легочной гипертензии
WO2025129108A1 (en) Methods of treating a cancer in an individual
WO2025049962A1 (en) Combination cancer treatments with a composition comprising an mtor pathway inhibitor
WO2024243413A1 (en) Combination therapy with a mtor inhibitor and a multi-tyrosine kinase inhibitor for treating soft tissue sarcoma
WO2024228964A1 (en) Treatments comprising an mtor inhibitor nanoparticle composition
HK40007412A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
HK1173975B (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
HK1173977B (en) Nanoparticle comprising rapamycin and albumin as anticancer agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211214